SG Americas Securities LLC Has $597,000 Stake in Progyny, Inc. (NASDAQ:PGNY)

SG Americas Securities LLC reduced its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 33.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,613 shares of the company's stock after selling 17,539 shares during the quarter. SG Americas Securities LLC's holdings in Progyny were worth $597,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. State Street Corp increased its stake in shares of Progyny by 4.5% during the third quarter. State Street Corp now owns 3,113,654 shares of the company's stock valued at $52,185,000 after acquiring an additional 134,861 shares during the period. International Assets Investment Management LLC lifted its holdings in shares of Progyny by 1,576.0% in the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock valued at $42,991,000 after buying an additional 2,412,068 shares during the period. Pacer Advisors Inc. boosted its stake in Progyny by 12,579.4% during the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock valued at $41,777,000 after buying an additional 2,472,983 shares in the last quarter. Invenomic Capital Management LP acquired a new position in Progyny during the third quarter worth about $29,509,000. Finally, Fort Washington Investment Advisors Inc. OH raised its position in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after acquiring an additional 695,740 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Transactions at Progyny

In other Progyny news, CEO Peter Anevski bought 209,500 shares of the firm's stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at approximately $6,392,384.24. The trade was a 90.32 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman David J. Schlanger purchased 150,000 shares of the business's stock in a transaction dated Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Progyny Price Performance

Progyny stock traded up $0.39 during mid-day trading on Monday, hitting $23.56. The company's stock had a trading volume of 677,355 shares, compared to its average volume of 1,970,241. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08. The company has a market cap of $2.01 billion, a PE ratio of 40.55, a price-to-earnings-growth ratio of 2.32 and a beta of 1.31. The firm's 50 day moving average is $17.62 and its 200 day moving average is $19.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company had revenue of $286.63 million during the quarter, compared to analysts' expectations of $296.85 million. During the same period last year, the company earned $0.16 earnings per share. Progyny's revenue for the quarter was up 2.0% compared to the same quarter last year. As a group, analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Analyst Upgrades and Downgrades

PGNY has been the subject of several research reports. Bank of America reduced their price objective on shares of Progyny from $22.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Truist Financial restated a "hold" rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Canaccord Genuity Group cut their price objective on Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research report on Wednesday, November 13th. Finally, Barclays decreased their target price on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $25.50.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.